LFG
PTGX icon

Larson Financial Group’s Protagonist Therapeutics PTGX Stock Holding History

Larson Financial Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
976
+157
+19% +$16.4K ﹤0.01% 1086
2026
Q1 		$86.3K Buy
819
+648
+379% +$57.4K ﹤0.01% 1065
2025
Q4 		$14.9K Buy
171
+17
+11% +$1.39K ﹤0.01% 1880
2025
Q3 		$10.2K Buy
154
+128
+492% +$7.28K ﹤0.01% 2003
2025
Q2 		$1.44K Sell
26
-100
-79% -$4.8K ﹤0.01% 2528
2025
Q1 		$6.09K Buy
126
+111
+740% +$4.65K ﹤0.01% 1829
2024
Q4 		$579 Sell
15
-2
-12% -$87 ﹤0.01% 2163
2024
Q3 		$765 Buy
+17
New +$687 ﹤0.01% 2042

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Larson Financial Group's PTGX Position: Q2 2026 in Review

Larson Financial Group increased its Protagonist Therapeutics (PTGX) stake by 19% in Q2 2026, buying an estimated $16.4K and bringing the position to 976 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Larson Financial Group first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Larson Financial Group held 976 shares of Protagonist Therapeutics worth $120K as of Q2 2026.
  • Larson Financial Group bought 157 Protagonist Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Protagonist Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1086 holding.
  • Larson Financial Group first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.